Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease.
Med Clin (Barc)
; 160(3): 113-117, 2023 02 10.
Article
em En, Es
| MEDLINE
| ID: mdl-36088128
ABSTRACT
INTRODUCTION:
Thyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder.OBJECTIVES:
To analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED.METHODS:
A retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021.RESULTS:
Eleven patients were included with a mean age of 52±12 (range 35-67) years. Nine patients were female and two were male. Patients received a median of 5±3.2 doses. Twenty out of twenty-four eyes achieved inactivation of TED at week 16. Proptosis response was achieved in 6/8 patients and diplopia response in 3/8 patients. The GO-QOL questionnaire showed clinically significant improvement in 9/11 patients. No serious adverse effects were reported during tocilizumab treatment. One patient required decompressive surgery 15 months after tocilizumab therapy.CONCLUSION:
The results obtained show that the use of tocilizumab in the treatment of this pathology can be a good alternative.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Oftalmopatia de Graves
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
/
Es
Revista:
Med Clin (Barc)
Ano de publicação:
2023
Tipo de documento:
Article